Antonin de Fougerolles explains the development of LNPs which was fundamental in enabling COVID mRNA vaccines. Dr. de Fougerolles also talks on novel delivery methods such as GalNAc conjugates and exosomes.

Despite initial scepticism, RNA therapeutics have proven to be effective for a wide range of diseases and conditions. We are still in a pivotal era of the field, with many new and exciting research projects underway to discover novel applications.

mRNA delivery techniques took a long time to come to fruition, but recent advancements have enabled production at a scale never seen before.

Beyond the blood–brain barrier, the pulmonary power of nebulisers, and RNA science in the post-COVID era

RNA based therapeutics, particularly mRNA, has been experiencing a period of rapid growth, partly due to the influx of funding for mRNA Covid-19 Vaccines. One area that has the potential to benefit from mRNA vaccines is cancer. There are various techniques that have potential to combat the deadly disease.   

This event brought over 600 leading industry minds together to discuss the latest crucial developments in RNA based therapeutics, from mRNA in vaccine development through to microRNA, siRNA, as well as antisense and RNA interference. RNA Therapeutics & Delivery US: Online featured two days of cutting-edge exhibitions and knowledge sharing, consisting of over 30 presentations, roundtables, panel discussions and ask-the-expert Q&As taking place across both days of the event.